Key result
Addition of verapamil to chronic digoxin therapy decreased mean resting heart rate from 87 to 72 beats/min and exercise heart rate from 151 to 106 beats/min.
Why the study?
Does the addition of verapamil to digoxin reduce heart rate in patients with chronic atrial fibrillation?
Does the addition of verapamil to digoxin reduce heart rate in patients with chronic atrial fibrillation?
The addition of verapamil to digoxin effectively suppresses ventricular response in chronic atrial fibrillation but significantly increases serum digoxin concentrations.
Answers are grounded in this paper and cite their sources.
May support adjunctive verapamil for rate control in chronic AF; leaves open digoxin interaction risks for prospective trials.
The safety, efficacy, and pharmacologic effect of combined verapamil and digoxin were studied in 10 patients with chronic atrial fibrillation.Heart rate recordings, treadmill exercise tests, physical examina- tions and serum digoxin concentrations during chronic digoxin therapy were compared with those after the acute administration of verapamil and 1, 2, 4, 6 and 10 weeks after the addition of oral verapamil to digoxin therapy.After both i.v. and chronic oral verapamil administration, resting and exercise heart rates were significantly lower.Increasing serum concentrations of verapamil correlated with increasing suppression of heart rate at rest and during exercise.The mean resting heart rate by 24-hour ambulatory ECG decreased from 87 ± 9 beats/min to 72 6 beats/min.The mean treadmill exercise heart rate decreased more markedly, from a mean of 151 26 beats/min to 106 ± 22 beats/min (both p < 0.001).During chronic therapy, heart rate reductions were seen 1 week after the addition of verapamil and were maintained without change for the duration of the trial.Blood pressures at rest and during exercise were unchanged.Cardiomegaly was present on the entry chest x-ray in six patients; after verapamil, heart size decreased in three and was unchanged in one; two patients had transient congestive heart failure that responded to diuretics.Serum digoxin levels increased from a mean of 1.6 ± 0.4 ng/ml to 2.7 + 0.9 ng/ml (p < 0.001) during verapamil.The in- crease was observed in hine of 10 patients but was not related to clinical signs of digitalis excess and no episodes of asystole were seen on the serial 24-hour ECGs.Chronic oral administration of verapamil, 320 mg/ day, resulted ih mean verapamil concentrations of 130-280 ng/ml (mean interdose concentration 140 ± 41 ng/ml) with great intersubject and intrasubject variability.We conclude that verapamil is effective in further suppressing the ventricular response rate in atrial fibrillation when given in combination with digitalis and can serve as an adjunct to digitalis therapy in the chronic management of patients with atrial fibrillation.VERAPAMIL is being studied extensively in the United States.Its major electrophysiologic action in conscious humans is to depress the slow response in the specialized conduction tissue in the sinoatrial node and the atrioventricular junction and impede atrio- ventricular conduction.' 2 This blocking effect of i.v.verapamil on atrioventricular conduction has been used to slow the ventricular response in atrial fibrilla- tion and flutter and to abolish supraventricular tachycardias due to nodal or atrioventricular reentry.'4Experience with administration of verapamil for the long-term management of atrial arrhythmias has been extremely limited.'This may be because caution is ad- vised when verapamil is used in combination with digitalis,10 which also inhibits the atrioventricular node.This study was designed to evaluate the efficacy and safety of combined verapamil and digitalis ad- ministration in patients with chronic atrial fibrillation and to define the relationship between the serum verapamil concentration and heart rate suppression during i.v. and long-term oral administration. Methods PatientsTen patients (seven males and three females), mean
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (1982) studied Chronic atrial fibrillation (n=10). Verapamil vs. Baseline (chronic digoxin therapy alone) was evaluated on Mean resting heart rate by 24-hour ambulatory ECG (beats/min) (p=< 0.001). Addition of verapamil to chronic digoxin therapy decreased mean resting heart rate from 87 to 72 beats/min and exercise heart rate from 151 to 106 beats/min.
Synapse has enriched 10 related papers. Consider them for comparative context: